Notice for obinutuzumab (Roche Products Pty Ltd)
Active ingredients
obinutuzumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for infusion
Indication
For the treatment of primary membranous nephropathy
Therapeutic area
Nephrology